Delayed Anthera data release shows increased heart risk

Share this article:

Data released at the American Heart Association meeting in Dallas over Anthera's discontinued Phase III cardiovascular disease drug varespladib has taken researchers by surprise: the company pulled the drug from testing last year, and the data shows that it boosted the risk of heart attack and stroke among patients. The New York Times and FierceBiotech find the data dump has triggered a slew of criticism against the pharmaceutical company for failure to provide this information earlier.

The Cleveland Clinic's Steven Nissen tells the NYT that Anthera “stonewalled every attempt to acquire the data,” and MedScape reports that the study's lead researcher, Stephen Nicholls, has taken a similar stance, telling the publication that Anthera withheld data “despite multiple requests.” The NYT says Nicholls asserts Anthera also failed to provide the agreed-upon, six-month follow-up for the majority of the clinical trial patients, a gap the NYT says makes it hard to confirm the drug increased mortality risk.

Anthera tells Fierce it did not delay publication.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.